CA9 and in situ carcinoma: After treatment with cytostatics in our study, the presence of CA IX was demonstrated in 92% (23/25) of IC and 62.5% (15/24) of CIS treated with PTX and 88.9% (8/9) of IC and 76% (19/25) of CIS treated with DOX.